Published:August 2011
No. of Pages: 48
Price: $515
Urology – Bard claims to be the worldwide market leader in urological diagnostic and interventional products with a focus on urological drainage, continence and prostate disease management. Through its Bard Medical Division, the company has expanded its urology business to products in the areas of infection control, continence management, prostate management and catheter stabilisation.
The Foley catheter, which Bard introduced in 1934, remains one of the most important products in the urological field. Other urology products include: surgical slings used to treat stress urinary incontinence; faecal incontinence products; natural and synthetic devices for the treatment of pelvic floor and vaginal prolapse; brachytherapy services, devices and radioactive seeds used to treat prostate cancer; intermittent urinary drainage catheters, urine monitoring and collection systems; ureteral stents; and specialty devices for ureteroscopic procedures and stone removal.
Bard entered the brachytherapy business in March 1998 with the purchase of Proseed Inc, which offered a turnkey programme that allows a hospital to implement brachytherapy treatment with lower investment cost and financial risk.
The acquisition of Venetec International in 2006 gave Bard access to the StatLock range of catheter stabilisation devices, which are used primarily to secure peripheral intravenous catheters.
Oncology – Bard’s oncology products and services are provided through Bard Access Systems, Bard Biopsy Systems and Bard Medical Division. They are designed for the treatment and management of various cancers and other diseases and disorders. These include specialty access catheters and ports; vascular access ultrasound devices, dialysis access catheters and enteral feeding devices.
The acquisition of Dymax Corp extended Bard Access Systems’ portfolio to include ultrasound systems that allow physicians to have real-time visualisation of needle placement.
The purchase of SenoRx in July 2010 enabled Bard to expand its biopsy business into the stereotactic X-ray segments.
Surgical Specialties – Bard maintains a complete line of advanced surgical specialty products and services to complement its focus on disease state management. These products are produced by Bard Medical and Davol and include implanted patches and fixation systems for hernia and other soft tissue repairs, irrigation devices for orthopaedic, laparoscopic and gynaecological procedures and products for topical haemostasis.
Other Products – The other product group includes irrigation, wound drainage and certain original equipment manufacturer (OEM) products.
Bard employs approximately 11,700 people. In 2010, the company generated net earnings of US$510 million on revenues of US$2.72 billion. Net sales in the first six months of 2011 reached US$1.43 billion.
Bard's shares are traded on the New York Stock Exchange. In August 2011, ValueAct Capital Management, a San Francisco, California-based hedge fund, announced that it held 6.5% of the company's shares.
This company report provides
Overview
Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company’s major competitors?
Key recent events in an “at a glance” format
Financial Review
Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
Table providing in-depth five-year financial analysis
Employee data, including breakdown by company division and geographic location
Strategic Focus
Investigates the company’s aims and its areas of focus
Products
Core product areas, key brands, product approvals and launches Research and Development
How much has been invested in R&D?
Where is the research based?
What alliances and agreements does the company have and with whom?
Manufacturing and Distribution
Identifying the company’s manufacturing locations
Sales and marketing facilities
Agreements
With whom has the company reached agreements and what do they involve?
Key contracts awarded
Mergers, Acquisitions, Minority Investments and Divestments
Litigation
Key Corporate Events
The report was produced as part of Medical Device Companies Analysis (MDCA).Table of Contents
OVERVIEW.1
FINANCIAL REVIEW3
First Half 2011 Financial Results 3
Vascular .4
Urology 4
Oncology .4
Surgical Specialty .5
Other 5
2010 Financial Results.5
Vascular .7
Urology 7
Oncology .8
Surgical Specialty .9
Other 9
Five-Year Financial Data10
Outlook11
Employees.11
STRATEGIC FOCUS12
PRODUCTS13
Vascular.14
Urology16
Oncology 18
Surgical Specialty.20
RESEARCH AND DEVELOPMENT.22
Product Pipeline.22
Studies and Trials 24
RESILIENT Trial.24
Bard Flair Endovascular Stent Graft24
MANUFACTURING AND DISTRIBUTION26
AGREEMENTS .27
Acacia Research’s Catheter Flushing Division27
Covalon Technologies.27
RTI Biologics 28
Thermal Scalpel 28
Philips.28
Medegen29
Genzyme29
TyRx Pharma29
Enpath Medical30
CardioTech International (now AdvanSource Biomaterials)30
Mentor30
Tissue Science Laboratories.30
Mediwatch .31
Floreane Medical Implants 31
Specialized Health Products International .31
Endologix.31
Collagen (Allergan)31
IS Pharma (formerly Maelor)32
Integra LifeSciences32
MERGERS AND ACQUISITIONS . 33
Romedex International 33
SenoRx .34
Bard Sendirian.34
FlowCardia.34
PacerView Technologies Assets.34
Spire Corporation Assets34
Y-Med34
Brennen Medical.35
Specialized Health Products International.35
LifeStent Product Line from Edwards Lifesciences.35
Inrad.35
Venetec International.36
PST’s Self-Expanding Stent Assets.36
Genyx Medical.36
Sorenson Medical’s Closed Suction Catheter System 36
Onux Medical 37
Bridger Biomedical .37
Prostate Services of America, Amertek Medical and Alton Design.37
Biomedical Instruments and Products GmbH’s Biopsy Device37
Source Tech Medical37
Imagyn Medical Technologies - Rights to Seed Business.37
NMT Medical’s Vena Cava Filter Business38
Mill-Rose Laboratories .38
Surgical Sense .38
Biosearch Medical Products’ Intermittent Urinary Catheter Business 38
Navarre Biomedical 38
Dymax 38
ProSeed38
Endomatrix 39
Impra 39
American Hydro-Surgical Instruments .39
Vas Cath .39
Angiomed 39
Cardial 39
Bainbridge Sciences .39
JOINT VENTURES 40
Medicon40
MINORITY INVESTMENTS .41
Hydromer 41
DIVESTITURES 42
Endoscopic Technologies Business42
Cardiopulmonary Business 42
Intra-Aortic Balloon Catheter and Pump Business.42
Coronary Cath Lab Business 42
Neonatal Product Line .42
Surgical Suction Product Line42
Sani-Spec Product Line.43
Sure-Closure System 43
Inspiron Division .43
MedSystems Division .43
Shield Healthcare Centers .43
Electromedical Systems .43
LITIGATION 44
Product Liability Matters. 44
Hernia Repair Implant Products 44
Women’s Health Products 44
Vena Cava Filter Products. 45
Hologic.45
Atrium Medical and Endologix.45
Covidien.45
W.L. Gore & Associates45
St Francis Medical Center. 46
US Department of Health and Human Services, OIG. 46
KEY CORPORATE EVENTS47
List of Tables
SUMMARY OPERATING RESULTS.iii
Recent Key Events2
Bard - First Half 2011 Financial Results.3
Bard - First Half 2011 Sales by Product Area.3
Bard - First Half 2011 Sales by Geographic Area.3
Bard - Annual Financial Results, 2006-20105
Bard - Annual Sales by Geographic Area, 2006-20106
Bard - Annual Sales by Product Area, 2006-20106
Bard – Five-Year Financial Summary.10
Bard – Product Contributions to Net Sales, 2006-201013
Key Vascular Products.14
Key Urology Products16
Key Oncology Products18
Key Surgical Specialty Products.20
Bard - Annual R&D Expenditure, 2006-201022
Bard – Principal Offices and Manufacturing Locations26
Agreements Summary27
Mergers and Acquisitions Summary.33
List of Charts
Bard - Annual Sales and Operating Income, 2006-20105
Bard - Annual Sales by Geographic Area, 2006-20106
Bard - Annual Sales by Product Area, 2006-20107
Bard - 2010 Sales by Product Group13
Bard - Annual Vascular Product Sales, 2006-2010.14
Bard - Annual Urology Product Sales, 2006-201016
Bard - Annual Oncology Product Sales, 2006-201018
Bard - Annual Surgical Specialty Product Sales, 2006-201021
No. of Pages: 48
Price: $515
Report Summary
Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available.
Headquartered in Murray Hill, New Jersey, US, C.R. Bard (Bard) develops and manufactures medical, surgical, diagnostic and patient care devices. The company sells its products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities in the US and in more than 100 other countries, principally in Europe and Japan. In general, Bard’s products are intended to be used once and then discarded or implanted either temporarily or permanently.
Bard medical device healthcare industry report serves through five divisions – Bard Access Systems Inc, Bard Electrophysiology Division, Bard Medical Division, Bard Peripheral Vascular Inc (including Bard Biopsy Systems) and Davol Inc – and four major product group categories – vascular, urology, oncology and surgical specialties. The company also has a product group of ‘Other Products’.
Vascular – Bard’s vascular products are produced by Bard Electrophysiology and Bard Peripheral Vascular. The company’s vascular products cover a wide range of minimally-invasive devices for the treatment of peripheral vascular disease (PVD) and heart arrhythmias. These products include: percutaneous transluminal angioplasty (PTA) catheters, chronic total occlusions (CTO) catheters, guidewires, introducers and accessories; peripheral vascular stents and stent grafts, vena cava filters and biopsy devices; electrophysiology products, including electrophysiology laboratory systems and diagnostic, therapeutic and temporary pacing electrode catheters; and fabrics, meshes and implantable vascular grafts.
Bard led the industry with the first angioplasty balloon catheter in 1980, giving cardiologists a safer and less costly alternative to open-heart procedures.
The January 2008 acquisition of the LifeStent range of stents from Edwards Lifesciences provided Bard with one of the broadest product offerings for peripheral vascular stenting.
The acquisition of Y-Med in November 2009 provided Bard with access to the VascuTrak catheter range.
More recently, the acquisition of FlowCardia in April 2010 expanded Bard’s portfolio of CTO endovascular products.
Headquartered in Murray Hill, New Jersey, US, C.R. Bard (Bard) develops and manufactures medical, surgical, diagnostic and patient care devices. The company sells its products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities in the US and in more than 100 other countries, principally in Europe and Japan. In general, Bard’s products are intended to be used once and then discarded or implanted either temporarily or permanently.
Bard medical device healthcare industry report serves through five divisions – Bard Access Systems Inc, Bard Electrophysiology Division, Bard Medical Division, Bard Peripheral Vascular Inc (including Bard Biopsy Systems) and Davol Inc – and four major product group categories – vascular, urology, oncology and surgical specialties. The company also has a product group of ‘Other Products’.
Vascular – Bard’s vascular products are produced by Bard Electrophysiology and Bard Peripheral Vascular. The company’s vascular products cover a wide range of minimally-invasive devices for the treatment of peripheral vascular disease (PVD) and heart arrhythmias. These products include: percutaneous transluminal angioplasty (PTA) catheters, chronic total occlusions (CTO) catheters, guidewires, introducers and accessories; peripheral vascular stents and stent grafts, vena cava filters and biopsy devices; electrophysiology products, including electrophysiology laboratory systems and diagnostic, therapeutic and temporary pacing electrode catheters; and fabrics, meshes and implantable vascular grafts.
Bard led the industry with the first angioplasty balloon catheter in 1980, giving cardiologists a safer and less costly alternative to open-heart procedures.
The January 2008 acquisition of the LifeStent range of stents from Edwards Lifesciences provided Bard with one of the broadest product offerings for peripheral vascular stenting.
The acquisition of Y-Med in November 2009 provided Bard with access to the VascuTrak catheter range.
More recently, the acquisition of FlowCardia in April 2010 expanded Bard’s portfolio of CTO endovascular products.
Urology – Bard claims to be the worldwide market leader in urological diagnostic and interventional products with a focus on urological drainage, continence and prostate disease management. Through its Bard Medical Division, the company has expanded its urology business to products in the areas of infection control, continence management, prostate management and catheter stabilisation.
The Foley catheter, which Bard introduced in 1934, remains one of the most important products in the urological field. Other urology products include: surgical slings used to treat stress urinary incontinence; faecal incontinence products; natural and synthetic devices for the treatment of pelvic floor and vaginal prolapse; brachytherapy services, devices and radioactive seeds used to treat prostate cancer; intermittent urinary drainage catheters, urine monitoring and collection systems; ureteral stents; and specialty devices for ureteroscopic procedures and stone removal.
Bard entered the brachytherapy business in March 1998 with the purchase of Proseed Inc, which offered a turnkey programme that allows a hospital to implement brachytherapy treatment with lower investment cost and financial risk.
The acquisition of Venetec International in 2006 gave Bard access to the StatLock range of catheter stabilisation devices, which are used primarily to secure peripheral intravenous catheters.
Oncology – Bard’s oncology products and services are provided through Bard Access Systems, Bard Biopsy Systems and Bard Medical Division. They are designed for the treatment and management of various cancers and other diseases and disorders. These include specialty access catheters and ports; vascular access ultrasound devices, dialysis access catheters and enteral feeding devices.
The acquisition of Dymax Corp extended Bard Access Systems’ portfolio to include ultrasound systems that allow physicians to have real-time visualisation of needle placement.
The purchase of SenoRx in July 2010 enabled Bard to expand its biopsy business into the stereotactic X-ray segments.
Surgical Specialties – Bard maintains a complete line of advanced surgical specialty products and services to complement its focus on disease state management. These products are produced by Bard Medical and Davol and include implanted patches and fixation systems for hernia and other soft tissue repairs, irrigation devices for orthopaedic, laparoscopic and gynaecological procedures and products for topical haemostasis.
Other Products – The other product group includes irrigation, wound drainage and certain original equipment manufacturer (OEM) products.
Bard employs approximately 11,700 people. In 2010, the company generated net earnings of US$510 million on revenues of US$2.72 billion. Net sales in the first six months of 2011 reached US$1.43 billion.
Bard's shares are traded on the New York Stock Exchange. In August 2011, ValueAct Capital Management, a San Francisco, California-based hedge fund, announced that it held 6.5% of the company's shares.
This company report provides
Overview
Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company’s major competitors?
Key recent events in an “at a glance” format
Financial Review
Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
Table providing in-depth five-year financial analysis
Employee data, including breakdown by company division and geographic location
Strategic Focus
Investigates the company’s aims and its areas of focus
Products
Core product areas, key brands, product approvals and launches Research and Development
How much has been invested in R&D?
Where is the research based?
What alliances and agreements does the company have and with whom?
Manufacturing and Distribution
Identifying the company’s manufacturing locations
Sales and marketing facilities
Agreements
With whom has the company reached agreements and what do they involve?
Key contracts awarded
Mergers, Acquisitions, Minority Investments and Divestments
Litigation
Key Corporate Events
The report was produced as part of Medical Device Companies Analysis (MDCA).
OVERVIEW.1
FINANCIAL REVIEW3
First Half 2011 Financial Results 3
Vascular .4
Urology 4
Oncology .4
Surgical Specialty .5
Other 5
2010 Financial Results.5
Vascular .7
Urology 7
Oncology .8
Surgical Specialty .9
Other 9
Five-Year Financial Data10
Outlook11
Employees.11
STRATEGIC FOCUS12
PRODUCTS13
Vascular.14
Urology16
Oncology 18
Surgical Specialty.20
RESEARCH AND DEVELOPMENT.22
Product Pipeline.22
Studies and Trials 24
RESILIENT Trial.24
Bard Flair Endovascular Stent Graft24
MANUFACTURING AND DISTRIBUTION26
AGREEMENTS .27
Acacia Research’s Catheter Flushing Division27
Covalon Technologies.27
RTI Biologics 28
Thermal Scalpel 28
Philips.28
Medegen29
Genzyme29
TyRx Pharma29
Enpath Medical30
CardioTech International (now AdvanSource Biomaterials)30
Mentor30
Tissue Science Laboratories.30
Mediwatch .31
Floreane Medical Implants 31
Specialized Health Products International .31
Endologix.31
Collagen (Allergan)31
IS Pharma (formerly Maelor)32
Integra LifeSciences32
MERGERS AND ACQUISITIONS . 33
Romedex International 33
SenoRx .34
Bard Sendirian.34
FlowCardia.34
PacerView Technologies Assets.34
Spire Corporation Assets34
Y-Med34
Brennen Medical.35
Specialized Health Products International.35
LifeStent Product Line from Edwards Lifesciences.35
Inrad.35
Venetec International.36
PST’s Self-Expanding Stent Assets.36
Genyx Medical.36
Sorenson Medical’s Closed Suction Catheter System 36
Onux Medical 37
Bridger Biomedical .37
Prostate Services of America, Amertek Medical and Alton Design.37
Biomedical Instruments and Products GmbH’s Biopsy Device37
Source Tech Medical37
Imagyn Medical Technologies - Rights to Seed Business.37
NMT Medical’s Vena Cava Filter Business38
Mill-Rose Laboratories .38
Surgical Sense .38
Biosearch Medical Products’ Intermittent Urinary Catheter Business 38
Navarre Biomedical 38
Dymax 38
ProSeed38
Endomatrix 39
Impra 39
American Hydro-Surgical Instruments .39
Vas Cath .39
Angiomed 39
Cardial 39
Bainbridge Sciences .39
JOINT VENTURES 40
Medicon40
MINORITY INVESTMENTS .41
Hydromer 41
DIVESTITURES 42
Endoscopic Technologies Business42
Cardiopulmonary Business 42
Intra-Aortic Balloon Catheter and Pump Business.42
Coronary Cath Lab Business 42
Neonatal Product Line .42
Surgical Suction Product Line42
Sani-Spec Product Line.43
Sure-Closure System 43
Inspiron Division .43
MedSystems Division .43
Shield Healthcare Centers .43
Electromedical Systems .43
LITIGATION 44
Product Liability Matters. 44
Hernia Repair Implant Products 44
Women’s Health Products 44
Vena Cava Filter Products. 45
Hologic.45
Atrium Medical and Endologix.45
Covidien.45
W.L. Gore & Associates45
St Francis Medical Center. 46
US Department of Health and Human Services, OIG. 46
KEY CORPORATE EVENTS47
List of Tables
SUMMARY OPERATING RESULTS.iii
Recent Key Events2
Bard - First Half 2011 Financial Results.3
Bard - First Half 2011 Sales by Product Area.3
Bard - First Half 2011 Sales by Geographic Area.3
Bard - Annual Financial Results, 2006-20105
Bard - Annual Sales by Geographic Area, 2006-20106
Bard - Annual Sales by Product Area, 2006-20106
Bard – Five-Year Financial Summary.10
Bard – Product Contributions to Net Sales, 2006-201013
Key Vascular Products.14
Key Urology Products16
Key Oncology Products18
Key Surgical Specialty Products.20
Bard - Annual R&D Expenditure, 2006-201022
Bard – Principal Offices and Manufacturing Locations26
Agreements Summary27
Mergers and Acquisitions Summary.33
List of Charts
Bard - Annual Sales and Operating Income, 2006-20105
Bard - Annual Sales by Geographic Area, 2006-20106
Bard - Annual Sales by Product Area, 2006-20107
Bard - 2010 Sales by Product Group13
Bard - Annual Vascular Product Sales, 2006-2010.14
Bard - Annual Urology Product Sales, 2006-201016
Bard - Annual Oncology Product Sales, 2006-201018
Bard - Annual Surgical Specialty Product Sales, 2006-201021
